EMA Authorised: Clopidogrel Viatris (previously Clopidogrel Taw Pharma) (clopidogrel besilate) — Viatris Limited

View source ↗

Summary

The EMA has authorized Clopidogrel Viatris (clopidogrel besilate) for use in preventing thrombotic events in patients with peripheral vascular disease, stroke, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myocardial Infarction
• Peripheral Vascular Disease
• Stroke

Drugs mentioned

• Clopidogrel Viatris (clopidogrel besilate)

Snippet

Status: Authorised. Therapeutic area: Peripheral Vascular Diseases;Stroke;Myocardial Infarction. MAH: Viatris Limited. Decision date: 12/12/2025